Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Specific oncogenic activity of the Src-family tyrosine kinase c-Yes in colon carcinoma cells.
Sancier F, Dumont A, Sirvent A, Paquay de Plater L, Edmonds T, David G, Jan M, de Montrion C, Cogé F, Léonce S, Burbridge M, Bruno A, Boutin JA, Lockhart B, Roche S, Cruzalegui F. Sancier F, et al. Among authors: burbridge m. PLoS One. 2011 Feb 24;6(2):e17237. doi: 10.1371/journal.pone.0017237. PLoS One. 2011. PMID: 21390316 Free PMC article.
S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab.
Burbridge MF, Bossard CJ, Saunier C, Fejes I, Bruno A, Léonce S, Ferry G, Da Violante G, Bouzom F, Cattan V, Jacquet-Bescond A, Comoglio PM, Lockhart BP, Boutin JA, Cordi A, Ortuno JC, Pierré A, Hickman JA, Cruzalegui FH, Depil S. Burbridge MF, et al. Mol Cancer Ther. 2013 Sep;12(9):1749-62. doi: 10.1158/1535-7163.MCT-13-0075. Epub 2013 Jun 26. Mol Cancer Ther. 2013. PMID: 23804704
Fragment-Derived Selective Inhibitors of Dual-Specificity Kinases DYRK1A and DYRK1B.
Lee Walmsley D, Murray JB, Dokurno P, Massey AJ, Benwell K, Fiumana A, Foloppe N, Ray S, Smith J, Surgenor AE, Edmonds T, Demarles D, Burbridge M, Cruzalegui F, Kotschy A, Hubbard RE. Lee Walmsley D, et al. Among authors: burbridge m. J Med Chem. 2021 Jul 8;64(13):8971-8991. doi: 10.1021/acs.jmedchem.1c00024. Epub 2021 Jun 18. J Med Chem. 2021. PMID: 34143631 Free article.
Structure-Guided Discovery of Potent and Selective DYRK1A Inhibitors.
Weber C, Sipos M, Paczal A, Balint B, Kun V, Foloppe N, Dokurno P, Massey AJ, Walmsley DL, Hubbard RE, Murray J, Benwell K, Edmonds T, Demarles D, Bruno A, Burbridge M, Cruzalegui F, Kotschy A. Weber C, et al. Among authors: burbridge m. J Med Chem. 2021 May 27;64(10):6745-6764. doi: 10.1021/acs.jmedchem.1c00023. Epub 2021 May 12. J Med Chem. 2021. PMID: 33975430
Antitumor activity of S 16020-2 in two orthotopic models of lung cancer.
Guilbaud N, Kraus-Berthier L, Saint-Dizier D, Rouillon MH, Jan M, Burbridge M, Pierré A, Atassi G. Guilbaud N, et al. Among authors: burbridge m. Anticancer Drugs. 1997 Mar;8(3):276-82. doi: 10.1097/00001813-199703000-00009. Anticancer Drugs. 1997. PMID: 9095333
Experimental antitumour activity of S 16020-2 in a panel of human tumours.
Kraus-Berthier L, Guilbaud N, Jan M, Saint-Dizier D, Rouillon MH, Burbridge MF, Pierré A, Atassi G. Kraus-Berthier L, et al. Among authors: burbridge mf. Eur J Cancer. 1997 Oct;33(11):1881-7. doi: 10.1016/s0959-8049(97)00232-3. Eur J Cancer. 1997. PMID: 9470851
Only a subset of Met-activated pathways are required to sustain oncogene addiction.
Bertotti A, Burbridge MF, Gastaldi S, Galimi F, Torti D, Medico E, Giordano S, Corso S, Rolland-Valognes G, Lockhart BP, Hickman JA, Comoglio PM, Trusolino L. Bertotti A, et al. Among authors: burbridge mf. Sci Signal. 2009 Dec 8;2(100):ra80. doi: 10.1126/scisignal.2000643. Sci Signal. 2009. Corrected and republished in: Sci Signal. 2009;2(102):er11. doi: 10.1126/scisignal.2102er11 PMID: 19996456 Free article. Corrected and republished.
70 results